211 related articles for article (PubMed ID: 16450317)
41. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
[TBL] [Abstract][Full Text] [Related]
42. Optimum management of type 2 diabetes--timely introduction, optimization and intensification of basal insulin.
Dailey G
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():5-13. PubMed ID: 18577152
[TBL] [Abstract][Full Text] [Related]
43. Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen.
de Boer H; Keizers R; Jansen M; Verschoor L; Ruineman-Koerts J
Diabetes Obes Metab; 2006 Sep; 8(5):517-23. PubMed ID: 16918586
[TBL] [Abstract][Full Text] [Related]
44. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Arnolds S; Rave K
Lancet; 2008 Aug; 372(9636):370-1; author reply 372. PubMed ID: 18675680
[No Abstract] [Full Text] [Related]
45. Starting insulin therapy in type 2 diabetes: lesson 1.
McCall AL
Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
[No Abstract] [Full Text] [Related]
46. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
[No Abstract] [Full Text] [Related]
47. Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.
Sudhakaran C; Kishore U; Anjana RM; Unnikrishnan R; Mohan V
Diabetes Technol Ther; 2011 Jan; 13(1):27-32. PubMed ID: 21175268
[TBL] [Abstract][Full Text] [Related]
48. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
49. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
[TBL] [Abstract][Full Text] [Related]
50. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
[TBL] [Abstract][Full Text] [Related]
51. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes.
Shaefer CF; Reid TS; Dailey G; Mabrey ME; Vlajnic A; Stuhr A; Stewart J; Zhou R
Postgrad Med; 2014 Oct; 126(6):93-105. PubMed ID: 25414938
[TBL] [Abstract][Full Text] [Related]
52. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
53. Does a patient-administered titration algorithm of insulin glargine improve glycemic control?
Edelman S
Nat Clin Pract Endocrinol Metab; 2006 Feb; 2(2):78-9. PubMed ID: 16932261
[No Abstract] [Full Text] [Related]
54. [Long acting insulin analogs: possibly more stable glucose regulation].
Huvers F
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1674-8. PubMed ID: 15453119
[TBL] [Abstract][Full Text] [Related]
55. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
56. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
57. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
Cardiovasc Diabetol; 2009 Jan; 8():3. PubMed ID: 19152692
[TBL] [Abstract][Full Text] [Related]
58. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
[TBL] [Abstract][Full Text] [Related]
59. Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine.
Davies M; Khunti K
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():42-9. PubMed ID: 18577156
[TBL] [Abstract][Full Text] [Related]
60. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
